ENZON INC
10-K, EX-27, 2000-09-28
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: ENZON INC, 10-K, EX-23.0, 2000-09-28
Next: WENDT BRISTOL HEALTH SERVICES CORP, 10-K, 2000-09-28



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial  information  extracted from the Enzon,
Inc. and  Subsidiaries  Consolidated  Balance  Sheet as of June 30, 2000 and the
Consolidated  Statement  of  Operations  for the year ended June 30, 2000 and is
qualified in its entirety by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>               JUN-30-2000
<PERIOD-END>                    JUN-30-2000
<CASH>                          $31,935,410
<SECURITIES>                              0
<RECEIVABLES>                     5,442,455
<ALLOWANCES>                              0
<INVENTORY>                         946,717
<CURRENT-ASSETS>                 57,580,744
<PP&E>                           12,439,729
<DEPRECIATION>                   10,650,859
<TOTAL-ASSETS>                  130,252,250
<CURRENT-LIABILITIES>             8,172,171
<BONDS>                                   0
                     0
                              70
<COMMON>                            408,381
<OTHER-SE>                      120,553,713
<TOTAL-LIABILITY-AND-EQUITY>    120,962,164
<SALES>                          15,591,488
<TOTAL-REVENUES>                 17,017,797
<CGS>                             4,888,357
<TOTAL-COSTS>                    26,227,247
<OTHER-EXPENSES>                          0
<LOSS-PROVISION>                          0
<INTEREST-EXPENSE>                    4,051
<INCOME-PRETAX>                 (6,306,464)
<INCOME-TAX>                              0
<INCOME-CONTINUING>             (6,306,464)
<DISCONTINUED>                            0
<EXTRAORDINARY>                           0
<CHANGES>                                 0
<NET-INCOME>                    (6,306,464)
<EPS-BASIC>                          (0.17)
<EPS-DILUTED>                        (0.17)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission